慢性肺高血圧症治療の世界市場レポート 2025年

慢性肺高血圧症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で89億5,000万米ドルに成長します。予測期間の成長は、効果的な治療法に対する需要の高まり、投資の増加、医薬品開発に対する政府支援の拡大、先進的治療薬に対する需要の高まり、意識の高まり、慢性脳損傷の発生率の上昇などに起因しています。主な動向としては、新薬や治療法の開発、技術の発展、製薬会社、研究機関、ヘルスケア機関との提携、新しい分子経路の特定、政府やヘルスケア機関からの投資の増加、新しい治療法の革新などが挙げられます。

心血管疾患の高い負担が、今後数年間の慢性肺高血圧症治療市場の成長を促進すると予想されます。心血管疾患には、冠動脈疾患、心不全、脳卒中など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。これらの疾患の有病率の増加は、不健康な食生活、運動不足、タバコの使用、過度のアルコール摂取、肥満、高血圧、糖尿病、高齢化などの危険因子と関連しています。慢性肺高血圧症治療は、肺動脈圧を下げ、心機能を改善し、心不全や関連合併症のリスクを軽減することで、心臓血管の健康に重要な役割を果たしています。例えば、2023年12月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、冠動脈性心疾患（CHD）による医師認定の死亡者数が2021年の1万4,100人から2022年には1万4,900人に増加したと報告しました。このような心血管疾患の負担増が、慢性肺高血圧症治療市場の拡大に寄与しています。

慢性肺高血圧症治療市場の主要企業は、患者のコンプライアンスを高め、利便性を向上させ、より的を絞った治療オプションを提供するために、皮下注射などの革新的なソリューションを優先しています。皮下注射は、皮下に持続的に薬剤を投与することで、肺動脈圧を効果的に低下させ、肺高血圧症患者の血流を改善します。例えば、2024年3月、米国の製薬会社であるMerck &Co Inc.は、米国食品医薬品局（FDA）がWinrevair（sotatercept-csrk）を承認したと発表し、肺動脈性肺高血圧症（PAH）治療に大きな進歩をもたらしました。この革新的な治療法は、PAHに対する画期的な選択肢として際立った効果をもたらします。臨床試験では、WHO機能分類において、プラセボ群では14％であったのに対し、Winrevairでは29％の患者で改善が認められ、患者のQOLの全体的な向上につながりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性肺高血圧症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の慢性肺高血圧症治療市場：成長率分析
• 世界の慢性肺高血圧症治療市場の実績：規模と成長, 2019-2024
• 世界の慢性肺高血圧症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性肺高血圧症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性肺高血圧症治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンドセリン受容体拮抗薬
• ホスホジエステラーゼ（PDE-5）阻害剤
• プロスタサイクリン類似体
• 可溶性グアニル酸シクラーゼ（SGC）刺激剤
• 世界の慢性肺高血圧症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内または皮下
• 吸入
• 世界の慢性肺高血圧症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の慢性肺高血圧症治療市場エンドセリン受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボセンタン
• アンブリセンタン
• マシテンタン
• 世界の慢性肺高血圧症治療市場ホスホジエステラーゼ（PDE-5）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シルデナフィル
• タダラフィル
• バルデナフィル
• 世界の慢性肺高血圧症治療市場プロスタサイクリン類似体のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポプロステノール
• トレプロスチニル
• イロプロスト
• 世界の慢性肺高血圧症治療市場可溶性グアニル酸シクラーゼ（SGC）刺激剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リオシグアト

第7章 地域別・国別分析

• 世界の慢性肺高血圧症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性肺高血圧症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性肺高血圧症治療市場：競合情勢
• 慢性肺高血圧症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GSK（GlaxoSmithKline）
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Boehringer Ingelheim
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Sumitomo Pharma Co. Ltd.
• Insmed
• Cereno Scientific
• Roivant Sciences
• LGM Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性肺高血圧症治療市場2029：新たな機会を提供する国
• 慢性肺高血圧症治療市場2029：新たな機会を提供するセグメント
• 慢性肺高血圧症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic pulmonary hypertension (PH) treatment involves managing elevated blood pressure in the lungs to enhance heart function and overall quality of life. This includes medications to lower pressure, oxygen therapy, and diuretics to alleviate symptoms. Advanced treatments may involve pulmonary rehabilitation, lifestyle modifications, and, if necessary, medical procedures. In severe cases, surgical interventions might be considered.

The primary drug categories for chronic pulmonary hypertension include endothelin receptor antagonists (ERAs), phosphodiesterase (PDE-5) inhibitors, prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. ERAs work by blocking endothelin to manage pulmonary hypertension and enhance quality of life. These medications are available in different forms, including oral, intravenous, subcutaneous, and inhalational routes, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic pulmonary hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides chronic pulmonary hypertension treatment market statistics, including the chronic pulmonary hypertension treatment industry global market size, regional shares, competitors with the chronic pulmonary hypertension treatment market share, detailed chronic pulmonary hypertension treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pulmonary hypertension treatment industry. This chronic pulmonary hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic pulmonary hypertension treatment market size has grown strongly in recent years. It will grow from $6.82 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be credited to the rising prevalence of chronic pulmonary hypertension, an increase in drug approvals, favorable reimbursement policies, growing healthcare expenditure, and an aging population.

The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $8.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be credited to the rising demand for effective treatments, increasing investments, greater government support for drug development, growing demand for advanced therapeutics, heightened awareness, and the rising incidence of chronic brain injuries. Key trends include the development of new drugs and therapies, technological advancements, collaborations with pharmaceutical companies, research institutions, and healthcare organizations, identification of new molecular pathways, increased investments from governments and healthcare organizations, and the innovation of new therapies.

The high burden of cardiovascular diseases is expected to drive the growth of the chronic pulmonary hypertension treatment market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increasing prevalence of these diseases is linked to risk factors such as unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Chronic pulmonary hypertension treatment plays a crucial role in cardiovascular health by lowering pulmonary artery pressure, improving heart function, and reducing the risk of heart failure and related complications. For example, in December 2023, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. This rising burden of cardiovascular diseases is contributing to the expansion of the chronic pulmonary hypertension treatment market.

Leading companies in the chronic pulmonary hypertension treatment market are prioritizing innovative solutions, such as subcutaneous injections, to enhance patient compliance, improve convenience, and offer more targeted treatment options. Subcutaneous injection delivers continuous medication under the skin, effectively lowering pulmonary artery pressure and improving blood flow in patients with pulmonary hypertension. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), marking a major advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy provides significant benefits, setting it apart as a groundbreaking option for PAH. Clinical trials showed that Winrevair improved WHO functional class in 29% of patients, compared to 14% in the placebo group, leading to overall enhancements in patients' quality of life.

In October 2024, Liquidia Corporation, a US-based biopharmaceutical company, partnered with Pharmosa Biopharm to accelerate the development and commercialization of L606. This collaboration aims to advance L606, an inhaled treprostinil therapy, to enhance treatment options for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharmosa Biopharm, a Taiwan-based biotechnology company, specializes in the research, development, and commercialization of pharmaceuticals and medical devices.

Major players in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, and Liquidia Technologies.

North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in chronic pulmonary hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic pulmonary hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic pulmonary hypertension treatment market consists of revenues earned by entities by providing services such as pharmacological treatment services, cardiopulmonary rehabilitation, telemedicine and remote patient monitoring, oxygen therapy, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pulmonary hypertension treatment market also includes sales of calcium channel blockers, pulmonary artery pressure monitoring systems, inhalation devices, and oxygen therapy equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Pulmonary Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic pulmonary hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic pulmonary hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic pulmonary hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Endothelin Receptor Antagonists; Phosphodiesterase (PDE-5) Inhibitors; Prostacyclin Analogs; Soluble Guanylate Cyclase (SGC) Stimulators
• 2) By Route Of Administration: Oral; Intravenous Or Subcutaneous; Inhalational
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Endothelin Receptor Antagonists: Bosentan; Ambrisentan; Macitentan
• 2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil; Tadalafil; Vardenafil
• 3) By Prostacyclin Analogs: Epoprostenol; Treprostinil; Iloprost
• 4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Pulmonary Hypertension Treatment Market Characteristics

3. Chronic Pulmonary Hypertension Treatment Market Trends And Strategies

4. Chronic Pulmonary Hypertension Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Pulmonary Hypertension Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Pulmonary Hypertension Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Pulmonary Hypertension Treatment Market Growth Rate Analysis
• 5.4. Global Chronic Pulmonary Hypertension Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Pulmonary Hypertension Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Pulmonary Hypertension Treatment Total Addressable Market (TAM)

6. Chronic Pulmonary Hypertension Treatment Market Segmentation

• 6.1. Global Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endothelin Receptor Antagonists
• Phosphodiesterase (PDE-5) Inhibitors
• Prostacyclin Analogs
• Soluble Guanylate Cyclase (SGC) Stimulators
• 6.2. Global Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous Or Subcutaneous
• Inhalational
• 6.3. Global Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Chronic Pulmonary Hypertension Treatment Market, Sub-Segmentation Of Endothelin Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bosentan
• Ambrisentan
• Macitentan
• 6.5. Global Chronic Pulmonary Hypertension Treatment Market, Sub-Segmentation Of Phosphodiesterase (PDE-5) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sildenafil
• Tadalafil
• Vardenafil
• 6.6. Global Chronic Pulmonary Hypertension Treatment Market, Sub-Segmentation Of Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoprostenol
• Treprostinil
• Iloprost
• 6.7. Global Chronic Pulmonary Hypertension Treatment Market, Sub-Segmentation Of Soluble Guanylate Cyclase (SGC) Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Riociguat

7. Chronic Pulmonary Hypertension Treatment Market Regional And Country Analysis

• 7.1. Global Chronic Pulmonary Hypertension Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Pulmonary Hypertension Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market

• 8.1. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Pulmonary Hypertension Treatment Market

• 9.1. China Chronic Pulmonary Hypertension Treatment Market Overview
• 9.2. China Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Pulmonary Hypertension Treatment Market

• 10.1. India Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Pulmonary Hypertension Treatment Market

• 11.1. Japan Chronic Pulmonary Hypertension Treatment Market Overview
• 11.2. Japan Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Pulmonary Hypertension Treatment Market

• 12.1. Australia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Pulmonary Hypertension Treatment Market

• 13.1. Indonesia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Pulmonary Hypertension Treatment Market

• 14.1. South Korea Chronic Pulmonary Hypertension Treatment Market Overview
• 14.2. South Korea Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Pulmonary Hypertension Treatment Market

• 15.1. Western Europe Chronic Pulmonary Hypertension Treatment Market Overview
• 15.2. Western Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Pulmonary Hypertension Treatment Market

• 16.1. UK Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Pulmonary Hypertension Treatment Market

• 17.1. Germany Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Pulmonary Hypertension Treatment Market

• 18.1. France Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Pulmonary Hypertension Treatment Market

• 19.1. Italy Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Pulmonary Hypertension Treatment Market

• 20.1. Spain Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Pulmonary Hypertension Treatment Market

• 21.1. Eastern Europe Chronic Pulmonary Hypertension Treatment Market Overview
• 21.2. Eastern Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Pulmonary Hypertension Treatment Market

• 22.1. Russia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Pulmonary Hypertension Treatment Market

• 23.1. North America Chronic Pulmonary Hypertension Treatment Market Overview
• 23.2. North America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Pulmonary Hypertension Treatment Market

• 24.1. USA Chronic Pulmonary Hypertension Treatment Market Overview
• 24.2. USA Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Pulmonary Hypertension Treatment Market

• 25.1. Canada Chronic Pulmonary Hypertension Treatment Market Overview
• 25.2. Canada Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Pulmonary Hypertension Treatment Market

• 26.1. South America Chronic Pulmonary Hypertension Treatment Market Overview
• 26.2. South America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Pulmonary Hypertension Treatment Market

• 27.1. Brazil Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Pulmonary Hypertension Treatment Market

• 28.1. Middle East Chronic Pulmonary Hypertension Treatment Market Overview
• 28.2. Middle East Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Pulmonary Hypertension Treatment Market

• 29.1. Africa Chronic Pulmonary Hypertension Treatment Market Overview
• 29.2. Africa Chronic Pulmonary Hypertension Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Pulmonary Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Pulmonary Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Pulmonary Hypertension Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chronic Pulmonary Hypertension Treatment Market Competitive Landscape
• 30.2. Chronic Pulmonary Hypertension Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Pulmonary Hypertension Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GSK (GlaxoSmithKline)
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Gilead Sciences Inc.
• 31.7. Boehringer Ingelheim
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Sumitomo Pharma Co. Ltd.
• 31.12. Insmed
• 31.13. Cereno Scientific
• 31.14. Roivant Sciences
• 31.15. LGM Pharma

32. Global Chronic Pulmonary Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Pulmonary Hypertension Treatment Market

34. Recent Developments In The Chronic Pulmonary Hypertension Treatment Market

35. Chronic Pulmonary Hypertension Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Pulmonary Hypertension Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Pulmonary Hypertension Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Pulmonary Hypertension Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer